EHS
EHS

Canagliflozin not associated with increased risk for fracture



Compared with a glucagon-line peptide-1 (GLP-1) agonist, canagliflozin was not associated with an increased risk for fracture in patients with type 2 diabetes at relatively low risk for fracture. Findings from a multidatabase cohort study are published in Annals of Internal Medicine.

Source link

EHS
Back to top button